GALR2 and early-onset autosomal dominant Alzheimer disease: Several learning and memory disorders, such as Alzheimer’s disease, age-related cognitive decline, and certain forms of amnesia, could potentially benefit from therapies targeting the NPY1R-GALR2 pathway.